Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 105.86
BTX's Cash to Debt is ranked higher than
52% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. BTX: 105.86 )
Ranked among companies with meaningful Cash to Debt only.
BTX' s 10-Year Cash to Debt Range
Min: 0.01  Med: 10000.00 Max: No Debt
Current: 105.86
Equity to Asset 0.38
BTX's Equity to Asset is ranked lower than
79% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BTX: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
BTX' s 10-Year Equity to Asset Range
Min: -45.87  Med: 0.40 Max: 0.99
Current: 0.38
-45.87
0.99
F-Score: 3
Z-Score: -1.60
M-Score: -2.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -976.18
BTX's Operating margin (%) is ranked lower than
79% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. BTX: -976.18 )
Ranked among companies with meaningful Operating margin (%) only.
BTX' s 10-Year Operating margin (%) Range
Min: -9788.46  Med: -473.64 Max: -116.83
Current: -976.18
-9788.46
-116.83
Net-margin (%) -708.44
BTX's Net-margin (%) is ranked lower than
77% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. BTX: -708.44 )
Ranked among companies with meaningful Net-margin (%) only.
BTX' s 10-Year Net-margin (%) Range
Min: -9471.15  Med: -488.17 Max: -137.48
Current: -708.44
-9471.15
-137.48
ROE (%) -173.85
BTX's ROE (%) is ranked lower than
89% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. BTX: -173.85 )
Ranked among companies with meaningful ROE (%) only.
BTX' s 10-Year ROE (%) Range
Min: -2802.7  Med: -120.66 Max: -49.44
Current: -173.85
-2802.7
-49.44
ROA (%) -59.44
BTX's ROA (%) is ranked lower than
75% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. BTX: -59.44 )
Ranked among companies with meaningful ROA (%) only.
BTX' s 10-Year ROA (%) Range
Min: -624.96  Med: -106.63 Max: -33.33
Current: -59.44
-624.96
-33.33
ROC (Joel Greenblatt) (%) -1840.95
BTX's ROC (Joel Greenblatt) (%) is ranked lower than
68% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. BTX: -1840.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21242.11  Med: -2340.14 Max: -800
Current: -1840.95
-21242.11
-800
Revenue Growth (3Y)(%) -3.90
BTX's Revenue Growth (3Y)(%) is ranked lower than
54% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. BTX: -3.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 7.70 Max: 128.9
Current: -3.9
0
128.9
EBITDA Growth (3Y)(%) 22.30
BTX's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. BTX: 22.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -48.9  Med: 7.70 Max: 63.9
Current: 22.3
-48.9
63.9
EPS Growth (3Y)(%) 16.30
BTX's EPS Growth (3Y)(%) is ranked higher than
73% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. BTX: 16.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BTX' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.6  Med: 9.80 Max: 67.1
Current: 16.3
-35.6
67.1
» BTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BTX Guru Trades in

BTX Guru Trades in

Q1 2014

BTX Guru Trades in Q1 2014

Jim Simons 51,700 sh (New)
» More
Q2 2014

BTX Guru Trades in Q2 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.71
BTX's P/B is ranked lower than
86% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. BTX: 12.71 )
Ranked among companies with meaningful P/B only.
BTX' s 10-Year P/B Range
Min: 5.65  Med: 12.42 Max: 83
Current: 12.71
5.65
83
P/S 48.34
BTX's P/S is ranked lower than
72% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. BTX: 48.34 )
Ranked among companies with meaningful P/S only.
BTX' s 10-Year P/S Range
Min: 4.83  Med: 39.63 Max: 124
Current: 48.34
4.83
124
Current Ratio 3.48
BTX's Current Ratio is ranked lower than
57% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. BTX: 3.48 )
Ranked among companies with meaningful Current Ratio only.
BTX' s 10-Year Current Ratio Range
Min: 0.02  Med: 4.55 Max: 76
Current: 3.48
0.02
76
Quick Ratio 3.44
BTX's Quick Ratio is ranked lower than
55% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BTX: 3.44 )
Ranked among companies with meaningful Quick Ratio only.
BTX' s 10-Year Quick Ratio Range
Min: 0.02  Med: 4.51 Max: 74
Current: 3.44
0.02
74
Days Inventory 98.99
BTX's Days Inventory is ranked higher than
58% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. BTX: 98.99 )
Ranked among companies with meaningful Days Inventory only.
BTX' s 10-Year Days Inventory Range
Min: 44.57  Med: 97.03 Max: 540.98
Current: 98.99
44.57
540.98
Days Sales Outstanding 76.69
BTX's Days Sales Outstanding is ranked lower than
60% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. BTX: 76.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
BTX' s 10-Year Days Sales Outstanding Range
Min: 91.79  Med: 95.33 Max: 98.86
Current: 76.69
91.79
98.86

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.16
BTX's Price/Median PS Value is ranked lower than
51% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. BTX: 1.16 )
Ranked among companies with meaningful Price/Median PS Value only.
BTX' s 10-Year Price/Median PS Value Range
Min: 0.13  Med: 1.28 Max: 14.66
Current: 1.16
0.13
14.66
Earnings Yield (Greenblatt) (%) -16.78
BTX's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. BTX: -16.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BTX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -18.7  Med: 0.00 Max: 0
Current: -16.78
-18.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BT3.Germany,
BioTime Inc was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. Its main focus is in the field of regenerative medicine; specifically human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. Its core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these pluripotent stem cells are being developed by the Company and its subsidiaries, for use in various fields of medicine, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. HyStem, Hextend, ESpy, PureStem, and PentaLyte are registered trademarks of the Company and Renevia, Premvia, ReGlyde, and ESpan are trademarks of the Company.
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BIOTIME INC Files SEC form 8-K, Other Events Jul 02 2015
William Annett Named Chief Executive Officer of OncoCyte Corporation Jun 16 2015
William Annett Named Chief Executive Officer of OncoCyte Corporation Jun 16 2015
BioTime to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
BioTime to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
OncoCyte’s Collaborators at The Wistar Institute Present Positive Clinical Interim Results of... May 19 2015
OncoCyte’s Collaborators at The Wistar Institute Present Positive Clinical Interim Results of... May 19 2015
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure May 19 2015
BIOTIME INC Financials May 16 2015
OncoCyte Corporation Completes Equity Financing Round May 14 2015
OncoCyte Corporation Completes Equity Financing Round May 14 2015
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 14 2015
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s... May 13 2015
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s... May 13 2015
BIOTIME INC Files SEC form 8-K, Other Events May 13 2015
BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments May 11 2015
BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments May 11 2015
BIOTIME INC Files SEC form 8-K, Results of Operations and Financial Condition May 11 2015
BIOTIME INC Files SEC form 10-Q, Quarterly Report May 08 2015
Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision May 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK